2-甲酰基-6-甲氧基-1H-吲哚 | 30464-93-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 2-甲酰基-6-甲氧基-1H-吲哚
• 英文名称: 6-methoxy-1H-indole-2-carbaldehyde
• CAS: 30464-93-8
• 化学式: C₁₀H₉NO₂
• mdl: MFCD01545314
• 分子量: 175.187
• InChiKey: HHQOSJVLKIANHF-UHFFFAOYSA-N

物化性质

• 沸点：
  375.2±22.0 °C(Predicted)
• 密度：
  1.273±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338,P304+P340,P405,P501
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  2-甲酰基-6-甲氧基-1H-吲哚 在 lithium aluminium tetrahydride 、 ammonium acetate 作用下， 以 四氢呋喃 为溶剂， 反应 6.5h， 生成 2-(6-methoxy-1H-indol-2-yl)ethanamine
  参考文献：
  名称：

  2-[N-Acylamino(C₁−C₃)alkyl]indoles as MT₁ Melatonin Receptor Partial Agonists, Antagonists, and Putative Inverse Agonists

  摘要：

  The synthesis of several novel indole melatonin analogues substituted at the 2-position with acylaminomethyl (8-11), acylaminoethyl (5a-k), or acylaminopropyl (13) side chains is reported. On the basis of a novel in vitro functional assay (specific binding of [S-35]GTP gamma S), which can discriminate agonist from partial agonist, antagonist, and inverse agonist ligands, Ba,g,h,j and 13 were shown to be partial agonists, 5d,e and 8-11 competitive antagonists, and 5b,c,k putative inverse agonists. Binding and functional assays were performed on cloned human MT1 receptor. Structure-activity relationship considerations indicate that N-[1-aryl-2-(4-methoxy-1H-indol-2-yl)(C-1-C-2)alkyl]alkanamides represent a lead structure for this type of ligands.

  DOI：

  10.1021/jm970721h
• 作为产物：
  描述：

  6-甲氧基-1H-吲哚-2-羧酸甲酯 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 、 sodium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 5.5h， 生成 2-甲酰基-6-甲氧基-1H-吲哚
  参考文献：
  名称：

  利血平生物碱的扭矩选择性 6π 电环化方法

  摘要：

  高度扭矩选择性的热三烯6π电环化控制利血平型生物碱的十二氢吲哚并[2,3- a ]苯并[ g ]喹嗪骨架的C3和C18立构中心之间的相对立体化学。采用串联交叉偶联/电环化方案使我们能够形成必要的三烯并确保其随后的环化。一种新型低温二溴乙烯酮缩醛克莱森重排建立了钯催化交叉偶联反应所需的环外二烯基溴化物前体。

  DOI：

  10.1021/ol302265z

文献信息

• Carbene‐Catalyzed Enantioselective Aromatic N‐Nucleophilic Addition of Heteroarenes to Ketones
  作者：Yonggui Liu、Guoyong Luo、Xing Yang、Shichun Jiang、Wei Xue、Yonggui Robin Chi、Zhichao Jin

  DOI：10.1002/anie.201912160

  日期：2020.1.2

  and optical purities. Our reaction involves the formation of an unprecedented aza-fulvene-type acylazolium intermediate. A broad range of N-heteroaromatic aldehydes and electron-deficient ketone substrates works effectively in this transformation. Several of the chiral N,O-acetal products afforded through this protocol exhibit excellent antibacterial activities against Ralstonia solanacearum (Rs) and

  杂芳基醛的芳族氮原子被卡宾催化剂活化以与酮亲电子试剂反应。以良好至优异的产率和光学纯度提供多功能的环状N，O-乙缩醛产物。我们的反应涉及空前的氮杂富烯型酰基唑鎓中间体的形成。各种各样的N-杂芳族醛和缺电子的酮底物可以有效地实现这种转化。通过该协议提供的几种手性N，O-乙缩醛产品表现出优异的抗青枯菌（Rsstonia solanacearum）的抗菌活性，在开发用于植物保护的新型农业化学品中具有重要的价值。
• [EN] IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS<br/>[FR] COMPOSÉS IMIDAZO-PYRIDINE À UTILISER EN TANT QU'INHIBITEURS DE PAD
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2019077631A1

  公开（公告）日：2019-04-25

  Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis. The process of preparation of the compounds of Formula (I), (II), and (III), their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, along with a pharmaceutical composition comprising a compound of Formula (I), Formula (II), Formula (III), or a pharmaceutically acceptable salt thereof have also been described.

  公式（I）、（II）和（III）的杂环化合物以及它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物在本文中被描述。本文描述的化合物、它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物是PAD4抑制剂，可能在治疗各种疾病中有用，例如类风湿关节炎、血管炎、系统性红斑狼疮、皮肤红斑狼疮、溃疡性结肠炎、癌症、囊性纤维化、哮喘、多发性硬化和牛皮癣。还描述了制备公式（I）、（II）和（III）的化合物、它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物的过程，以及包含公式（I）、公式（II）、公式（III）的化合物或其药学上可接受的盐的药物组合物。
• [EN] HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE PAD
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2019058393A1

  公开（公告）日：2019-03-28

  Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis.

  公式（I）、（II）和（III）的杂环化合物以及它们的多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物在此处描述。本文描述的化合物及其多晶形态、立体异构体、前药、溶剂合物、共晶体、中间体、药学上可接受的盐和代谢物是PAD4抑制剂，可能在治疗各种疾病中有用，例如类风湿关节炎、血管炎、系统性红斑狼疮、皮肤红斑狼疮、溃疡性结肠炎、癌症、囊性纤维化、哮喘、多发性硬化和牛皮癣。
• Highly Enantioselective Synthesis of Pyrroloindolones and Pyrroloquinolinones via an <i>N</i>-Heterocyclic Carbene-Catalyzed Cascade Reaction
  作者：Xiao-Yong Duan、Zhaohui Tian、Binghao Liu、Tao He、Liang-Liang Zhao、Mengdie Dong、Pengna Zhang、Jing Qi

  DOI：10.1021/acs.orglett.1c01203

  日期：2021.5.7

  NHC-catalyzed Michael/Mannich/lactamization cascade reaction of enals with either indole-2-carboxaldehyde-derived aldimines or indole-7-carboxaldehyde-derived aldimines is described. This protocol enables the rapid assembly of optically active pyrroloindolones and pyrroloquinolinones derivatives under mild conditions with high yields, excellent enantioselectivities, and a broad substrate scope.

  在这项工作中，描述了NHC催化的吲哚与吲哚-2-羧基醛衍生的亚胺或吲哚-7-甲醛醛衍生的亚胺的迈克尔/曼尼希/内酰胺化级联反应。该协议能够在温和条件下以高收率，优异的对映选择性和广泛的底物范围快速组装光学活性吡咯并吲哚酮和吡咯并喹啉酮衍生物。
• Base-dependent formation of cis and trans olefins and their application in the synthesis of 5-oxo-ETE receptor antagonists
  作者：Vivek Gore、Shishir Chourey、Qiuji Ye、Pranav Patel、Yannick Ouedraogo、Sylvie Gravel、William S. Powell、Joshua Rokach

  DOI：10.1016/j.bmcl.2014.05.090

  日期：2014.8

  receptor antagonists. In the course of the work, we have developed a procedure to selectively introduce a cis and trans double bond in an alkyl side chain. Reacting indolecarboxaldehydes with alkyl ylides using the Li base affords the trans olefins, whereas using the K base yields the cis olefins.

  5-Oxo-ETE是脂质介体中最有效的嗜酸性粒细胞趋化因子。我们已经开发出两种5-oxo-ETE受体拮抗剂。在工作过程中，我们开发了一种在烷基侧链中选择性引入顺式和反式双键的方法。使用Li碱使吲哚羧酸醛与烷基化物反应，得到反式烯烃，而使用K碱，产生顺式烯烃。